Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized risk-stratified pediatric Crohn's disease trial comparing methotrexate with thiopurines or adalimumab for maintenance of remission
MOH_2017-09-03_000771Phase 4Recruiting
- Sponsor
- PIBD-Net
- Start
- Oct 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methotrexate, mercaptopurine and adalimumab in Crohn's disease (4 arms), sponsored by PIBD-Net. Primary endpoints: Maintenance of remission over 1 year, Maintenance of remission over 1 year in low-risk group and 1 more. Started Oct 2016; status: recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2017-09-03_000771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-03_000771.